GC Biopharma

GC Biopharma Inventory

The Inventory of GC Biopharma (006280.KS) as of Oct 27, 2026 is 891.58 B KRW. In the previous year, Inventory was 746.58 B KRW — a change of 19.42% (higher).

Inventory

891.58 BKRW

YoY

19.42%

Last updated:

Inventory of GC Biopharma is 2025 891.58 B KRW. Inventory of GC Biopharma was 2024 746.58 B KRW. It decreases by 19.42% higher compared to the previous year.

The GC Biopharma Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
386.93 B KRW
Jan 1, 2019
406.56 B KRW
Jan 1, 2020
437.07 B KRW
Jan 1, 2021
454.98 B KRW
Jan 1, 2022
442.41 B KRW
Jan 1, 2023
516.25 B KRW
Jan 1, 2024
746.58 B KRW
Jan 1, 2025
891.58 B KRW
The GC Biopharma Inventory history
YEARInventoryYoY
891.58 BKRW+19.42%
746.58 BKRW+44.62%
516.25 BKRW+16.69%
442.41 BKRW-2.76%
454.98 BKRW+4.10%
437.07 BKRW+7.51%
406.56 BKRW+5.07%
386.93 BKRW+1.48%
381.27 BKRW+18.87%
320.75 BKRW-1.23%
324.73 BKRW+8.83%
298.40 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GC Biopharma Stock analysis

What does GC Biopharma do? GC Biopharma Corp generates revenue through the production and sale of pharmaceutical products such as blood products, general products, vaccines, over-the-counter drugs, diagnostic reagents, placental injections, cell therapies, and blood diagnostic products. The company also offers genome analysis services. Its primary customers include healthcare providers and institutions requiring pharmaceuticals and diagnostic solutions. The firm targets segments focused on biopharmaceutical manufacturing and genomic healthcare services. Green Cross Corp, the parent company, operates under the same business model, emphasizing pharmaceutical manufacturing and genomic services. The company's product portfolio spans blood-related treatments, vaccines, and advanced diagnostic tools, catering to both general medical needs and specialized healthcare applications. Revenue streams are derived from direct sales of these products and services to healthcare sectors. The business model integrates the production of traditional pharmaceuticals with innovative genomic services, creating a diversified revenue base. Key segments include blood product manufacturing, vaccine development, and diagnostic reagent sales, alongside cell therapy and placental injection offerings. Customers are primarily healthcare institutions and providers seeking comprehensive pharmaceutical and diagnostic solutions. GC Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Biopharma stock

Inventory of GC Biopharma is 891.58 B KRW in 2025.

Inventory of GC Biopharma changed from 746.58 B KRW to 891.58 B KRW, representing a 19.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory GC Biopharma since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's GC Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GC Biopharma

All Key Metrics — GC Biopharma